Company intelligence

ACET

Adicet Bio, Inc. · NASDAQ · Healthcare

Price$9.01+0.67% · +$0.06

Market cap84.23MEquity value

P / E-0.8Trailing ratio

Volume250.08KLatest session

Market data

ACET price chart

TradingView

Related signals

1 min delayed

Browse public ACET signals with their source context and measured market impact. Open any signal for its permanent analysis page.

ACETOct 7, 2025+10.63% since signal

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2

ACET shares fell 15% after $80 million direct offering announcement. Early ADI-001 trial data shows 100% renal response in lupus nephritis patients. Company plans to request FDA meeting for Phase 2 trial design in 2026. Stock reached $1.30 in premarket before news caused sharp decline.

View signal analysis

ACETJul 2, 2024

3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns

-Some clinical-stage biotech stocks have the potential for significant returns. -It is advisable to limit exposure to early-stage companies to 5% to 10% of the portfolio. -Three clinical-stage biotech stocks are highlighted as potential 10-baggers in 24 to 36 months. Price Impact Rating: Bullish Impact Horizon Rating: Long-term Type: Research Analysis

View signal analysis

Research